TrialRMD open2025

If the evidence is there, why are GLP-1 receptor agonists not on-label for hip and knee osteoarthritis in overweight patients?

Francesco Ursini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.